-

Transdermal Drug Delivery Devices - Medical Devices Pipeline Assessment, 2020 Report - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Transdermal Drug Delivery Devices - Medical Devices Pipeline Assessment, 2020" report has been added to ResearchAndMarkets.com's offering.

"Transdermal Drug Delivery Devices - Medical Devices Pipeline Assessment, 2020". Transdermal Drug Delivery Devices is a medicated adhesive patch that is placed on the skin to deliver a specific dose of medication through the skin and into the bloodstream.

Scope

  • Extensive coverage of the Transdermal Drug Delivery Devices under development
  • The report reviews details of major pipeline products which includes product description, licensing and collaboration details and other developmental activities
  • The report reviews the major players involved in the development of Transdermal Drug Delivery Devices and list all their pipeline projects
  • The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
  • The report provides key clinical trial data of ongoing trials specific to pipeline products
  • Recent developments in the segment / industry

Reasons to Buy

  • Formulate significant competitor information, analysis, and insights to improve R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of Transdermal Drug Delivery Devices under development
  • Develop market-entry and market expansion strategies
  • Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
  • In-depth analysis of the product's current stage of development, territory and estimated launch date

Key Topics Covered:

1 Tables & Figures

2 Introduction

2.1 Transdermal Drug Delivery Overview

3 Products under Development

3.1 Transdermal Drug Delivery - Pipeline Products by Stage of Development

3.2 Transdermal Drug Delivery - Pipeline Products by Segment

3.3 Transdermal Drug Delivery - Pipeline Products by Territory

3.4 Transdermal Drug Delivery - Pipeline Products by Regulatory Path

3.5 Transdermal Drug Delivery - Pipeline Products by Estimated Approval Date

3.6 Transdermal Drug Delivery - Ongoing Clinical Trials

4 Transdermal Drug Delivery - Pipeline Products under Development by Companies

4.1 Transdermal Drug Delivery Companies - Pipeline Products by Stage of Development

4.2 Transdermal Drug Delivery - Pipeline Products by Stage of Development

5 Transdermal Drug Delivery Companies and Product Overview

6 Transdermal Drug Delivery- Recent Developments 2977 Appendix

7 Appendix

Companies Mentioned

  • 3M Co
  • 4P Therapeutics LLC
  • Actuated Medical Inc
  • Adynxx Inc
  • Aequus Pharmaceuticals Inc
  • Agile Therapeutics Inc
  • Allergan Ltd
  • AMW GmbH
  • AngioSoma Inc
  • Apogee Technology Inc
  • Asahi Kasei Pharma Corp
  • ASCIL Biopharm
  • Avecho Biotechnology Ltd
  • Avro Life Sciences
  • Boryung Pharmaceutical Co Ltd
  • Burke Pharmaceuticals LLC
  • Candesant Biomedical Inc
  • Cassava Sciences Inc
  • CB Scientific Inc
  • Cerimon Pharmaceuticals, Inc. (Inactive)
  • Chrono Therapeutics Inc
  • Cipla Ltd
  • Clexio Biosciences Ltd
  • Corium Inc
  • Daewoong Pharmaceutical Co Ltd
  • DBV Technologies SA
  • DD Therapeutics LLC
  • Delpor Inc
  • Dermisonics Inc (Inactive)
  • Dharma Therapeutics, Inc. (Inactive)
  • Diomics Corp
  • Drexel University
  • DURECT Corp
  • Echo Therapeutics Inc
  • Emplicure AB
  • Endo International Plc
  • Extend Biosciences Inc
  • Fe3 Medical Inc
  • Futura Medical Plc
  • Georgia Institute of Technology
  • Georgia State University
  • Hisamitsu Pharmaceutical Co Inc
  • I M Sechenov Moscow State Medical University
  • Icure Pharmaceutical Inc
  • ImmuPatch
  • Indian Institute of Science
  • Indian Institute of Technology Bombay
  • InMed Pharmaceuticals Inc
  • Institute of Materials Research & Engineering
  • Intercell AG (Inactive)
  • Interstitial NS
  • Isis Biopolymer Inc (Inactive)
  • Janisys
  • KTH Royal Institute of Technology
  • Leo Pharma AS
  • Livzon Pharmaceutical Group Co Ltd
  • Lohmann Therapie-Systeme AG
  • Luye Pharma Group Ltd
  • Massachusetts Institute of Technology
  • Mayne Pharma Group Ltd
  • Medherant Ltd
  • MEDRx Co Ltd
  • MedRx, Inc.
  • Microdermics Inc
  • Micron Biomedical Inc
  • Micropoint Technologies Pte Ltd
  • mPhase Technologies Inc
  • National University of Singapore
  • Nemaura Pharma Ltd
  • NeuroDerm Ltd
  • Nitto Denko Corp
  • North Carolina State University
  • Noven Pharmaceuticals Inc
  • NutriBand Inc
  • Nuvo Pharmaceuticals Inc
  • PassPort Technologies Inc
  • Privo Technologies Inc
  • Prometheon Pharma LLC
  • Purdue University
  • Quoin Pharmaceuticals Ltd
  • Radius Health Inc
  • Ryah Medtech Inc
  • Samyang Biopharmaceuticals Corp
  • Scilex Ltd
  • Seelos Therapeutics, Inc.
  • Shenox Pharmaceuticals LLC
  • Sinsin Pharmaceutical Co Ltd
  • SK Chemicals Co Ltd
  • Skinject Inc
  • Sparsha Pharma International Pvt Ltd
  • Sree Chitra Tirunal Institute for Medical Sciences & Technology
  • Stanford University
  • Starton Therapeutics Inc
  • Syntropharma Ltd
  • Taho Pharmaceuticals Ltd
  • Technology Health Inc
  • Teikoku Pharma USA Inc
  • tesa Labtec GmbH
  • Teva Pharmaceutical Industries Ltd
  • Texas Tech University
  • The Sheikh Zayed Institute for Pediatric Surgical Innovation
  • TheraJect Inc
  • Therapeutic Systems Research Laboratories Inc
  • TheraSolve NV (Inactive)
  • Theratech, Inc.
  • Thrudermic LLC
  • Titan Pharmaceuticals Inc
  • Toa Eiyo Ltd
  • Transcu Group Limited (Inactive)
  • Transdermal Delivery Solutions Corp
  • Transdermal Specialties Inc
  • TransPharma Medical Ltd (Inactive)
  • Transport Pharmaceuticals Inc
  • University of Illinois at Chicago
  • University of Toronto
  • Vaxess Technologies Inc
  • Vaxxas Pty Ltd
  • Verndari Inc
  • ViiV Healthcare UK Ltd
  • Virpax Pharmaceuticals Inc
  • Vyteris, Inc. (Inactive)
  • Xel Pharmaceuticals Inc
  • XPhyto Therapeutic Corp
  • Zambon Italia Srl
  • Z-Cube Srl
  • ZetrOZ Inc
  • Zynerba Pharmaceuticals Inc

For more information about this report visit https://www.researchandmarkets.com/r/hkw8cx

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Research and Markets


Release Versions

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

More News From Research and Markets

Asia Pacific Mining Industry Review 2025: Production by Country, Major Operating Mines, Major Exploration, and Development Projects - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Asia Pacific Mining Review 2025" report has been added to ResearchAndMarkets.com's offering. The report contains an overview of the Asia Pacific mining industry including key macroeconomic trends, commodity price, and operating environment across major and emerging mining markets. It provides detailed information on production by country, major operating mines, major exploration, and development projects. Asia Pacific is one of the world's leading mining regions, e...

Fitness Apps Strategic Business Report 2025-2030: Subscription-Based Apps and At-Home Workouts Drive the Global Market at 13.5% CAGR - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Fitness Apps - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering. The global fitness apps market is anticipated to surge from a valuation of US$12.1 billion in 2024 to US$25.8 billion by 2030, reflecting a CAGR of 13.5% from 2024 to 2030. This comprehensive analysis offers key insights into market dynamics, technological advancements, consumer preferences, and the competitive landscape, enabling informed business decisions in thi...

$8.9 Billion FSO & VLC/Li-Fi Market Sizing and Investment Insights Report 2025-2032: The Shift Towards Digital and Smart Building Ecosystems Has Accelerated Adoption Worldwide - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "FSO & VLC/Li-Fi Market - Global Forecast 2025-2032" report has been added to ResearchAndMarkets.com's offering. The FSO & VLC/Li-Fi Market is rapidly advancing, redefining high-capacity, secure data connectivity across industries through innovative optical wireless communication solutions. As organizations seek robust, electromagnetic interference-free alternatives to traditional radio frequency systems, this market offers new opportunities for digital tran...
Back to Newsroom